Ivermectine Liconsa

Ivermectin, the active ingredient in Ivermectine Liconsa, is an anthelmintic (macrocyclic lactone) presented as an oral formulation for prescription use. It is employed to treat a range of parasitic infections in humans, including river blindness and various helminthic diseases.

GNH USA supplies Ivermectine Liconsa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice standards and provides regulatory documentation for import and export. Our global logistics network ensures timely delivery to diverse markets.

Ivermectin acts on a broad spectrum of parasitic organisms, providing therapeutic benefit in several helminthic and ectoparasitic diseases. - Onchocerciasis: reduces microfilarial load and helps prevent vision loss. - Strongyloidiasis: eliminates intestinal larvae and prevents hyperinfection. - Lymphatic filariasis: decreases adult worm burden and reduces disease transmission. - Scabies: kills Sarcoptes scabiei mites, relieving itching and skin lesions. - Pediculosis: eradicates head lice infestations by targeting nymphs and adults. - Other helminth infections: provides broad antiparasitic activity against various nematodes.

Adverse reactions to Ivermectine Liconsa are generally mild, but serious events can occur.

Common Side Effects: - Nausea - Dizziness - Abdominal pain - Diarrhea

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatic dysfunction or elevated liver enzymes - Neurologic toxicity including seizures or altered consciousness

Before prescribing Ivermectine Liconsa, clinicians should consider several safety precautions. - Pregnancy: safety not established; use only if potential benefit outweighs risk. - Breastfeeding: limited data; assess risk versus benefit before use. - Renal impairment: dose adjustment may be required; monitor renal function. - Concomitant neurotoxic drugs: avoid or use with caution due to additive toxicity. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Ivermectine Liconsa may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin) can markedly reduce ivermectin plasma concentrations. - Co‑administration with other neurotoxic agents (e.g., albendazole) may increase risk of neurologic adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: ivermectin may potentiate anticoagulant effect; monitor INR. - Macrolide antibiotics (e.g., erythromycin): may raise ivermectin levels; observe for toxicity. - Antiepileptic drugs: may affect seizure threshold; watch for changes in seizure control.